Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 16/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12829824 | 0.89 | FBP1 (0.52) | FBP1MEN1MAPTKMT2AHDAC6 | |
| SCHEMBL128635 | 0.81 | FBP1 (0.61) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL9883987 | 0.77 | FBP1 (0.52) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL18233032 | 0.74 | NPC1 (0.60) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL33525267 | 0.72 | IL6 (0.61) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL28479671 | 0.72 | CA1 (0.43) | FBP1 | |
| SCHEMBL15450959 | 0.72 | FBP1 (0.61) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL4399183 | 0.72 | L3MBTL1 (0.53) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL2706413 | 0.72 | NPC1 (0.49) | FBP1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL23095285 | 0.70 | NPC1 (0.48) | FBP1MEN1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | FBP1 707/4885MEN1 3187/4885MAPT 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.